The 5 analysts offering 12-month price forecasts for SpringWorks Therapeutics Inc have a median target of 105.00, with a high estimate of 137.00 and a low estimate of 104.00. The median estimate represents a +73.15% increase from the last price of 60.64.
The current consensus among 6 polled investment analysts is to Buy stock in SpringWorks Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.72
Reporting Date Nov 17
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.